ライフサイエンスコーパス: obese patient

1 h the supine PCNL may be preferable (e.g. in obese patients).

2 bin or fibrin(ogen) may limit pathologies in obese patients.

3 as weight loss, that may be advantageous in obese patients.

4 ase and anthropometric measures in Class III obese patients.

5 the risk of promoting insulin resistance in obese patients.

6 n blood microbiota are associated with LF in obese patients.

7 r optimal mechanical ventilation of morbidly obese patients.

8 odynamics and pharmacokinetic variability in obese patients.

9 lating neuromuscular-blocking agent doses in obese patients.

10 Outcome in the long term is best in super obese patients.

11 r fitness and survival in some overweight or obese patients.

12 y best performed using actual body weight in obese patients.

13 ry fitness and incident AF, especially among obese patients.

14 ese compared with nonobese, especially among obese patients.

15 mpared bariatric surgery with usual care for obese patients.

16 rnia (28.3% vs 14.8% vs 20.3%, P = 0.01) for obese patients.

17 isolated from subcutaneous adipose tissue of obese patients.

18 ment for the treatment of type 2 diabetes in obese patients.

19 s and improves insulin sensitivity (S(I)) in obese patients.

20 in resistance pattern compared with morbidly obese patients.

21 e performed safely and efficiently in mildly obese patients.

22 clear benefit to weight gain for overweight/obese patients.

23 ght and cardiovascular mortality in morbidly obese patients.

24 his population was even undetectable in some obese patients.

25 t outcomes observed in overweight and mildly obese patients.

26 for achieving clinical control of asthma in obese patients.

27 breaks down and shows low SUL values in very obese patients.

28 s found in adipose tissue of type 2 diabetic obese patients.

29 disease and may have a better prognosis than obese patients.

30 nitial type 2 diabetes mellitus remission in obese patients.

31 criterion and restricts surgery to severely obese patients.

32 c flux and treating metabolic pathologies in obese patients.

33 e turnover and accumulation of adipocytes in obese patients.

34 n a large single-center cohort of overweight/obese patients.

35 long-term weight loss strategy for morbidly obese patients.

36 IM1 were identified in 28 unrelated severely obese patients.

37 en normal weight patients were compared with obese patients.

38 and other metabolic risk factors in severely obese patients.

39 ed a significantly increased risk for DGF in obese patients.

40 tly related to electroanatomic remodeling in obese patients.

41 of mice fed a high-fat diet (HFD) as well as obese patients.

42 tsurgical elovl6 gene expression in morbidly obese patients.

43 and appears to be well tolerated in severely obese patients.

44 c use of leptin in overweight and moderately obese patients.

45 standing the pathogenesis of lung disease in obese patients.

46 regimens for iGAS may improve prognoses for obese patients.

47 ting neuromuscular-blocking agents doses for obese patients.

48 type are mobilized and infiltrate tumours in obese patients.

49 es of 15 obese patients compared with 16 non-obese patients.

50 ting when caring for critically ill morbidly obese patients.

51 oments were evident when caring for morbidly obese patients.

52 pose tissue (VAT) of metabolically unhealthy obese patients.

53 pe 2 diabetics (8.8% vs 5.5%; P = .046), and obese patients (11.7% vs 4.0%; P < .001).

54 Of these obese patients, 2256 (83%) agreed to participate and 188

55 motility and hormonal responses in morbidly obese patients after sleeve gastrectomy has not been det

56 Better survival for overweight and obese patients after ST-segment-elevation myocardial inf

57 Morbidly obese patients also benefited more from LT (88% mortalit

58 TIA1 is reported to be downregulated in obese patients, although it is not known if the effect i

59 Case-control study of 21 obese patients and 24 matched control participants.

60 d sleeve gastrectomy is feasible in morbidly obese patients and adds little additional operative time

61 est level of risk reduction was observed for obese patients and for long-segment Barrett's esophagus.

62 avenues to ameliorate glucose homeostasis in obese patients and improve the effectiveness of metformi

63 els of SREBP-1 are significantly elevated in obese patients and in animal models of obesity and type

64 on was almost 2 times higher among women and obese patients and more than 1.5 times higher among pati

65 cifically decreased in the adipose tissue of obese patients and murine models of genetic and nutritio

66 elopment of whole-body insulin resistance in obese patients and obese animal models.

67 lls, and p38 signaling is also suppressed in obese patients and obese animals.

68 ify factors associated with MetS in morbidly obese patients and predictors of its remission 12 months

69 on the safety of pancreas transplantation in obese patients and suggest that they may be directed to

70 To identify high-risk subgroups of obese patients and to examine the joint association of m

71 te to the pathogenesis of asthma severity in obese patients and warrant further investigation.

72 Obese patients are difficult to transport between emerge

73 ngs of nutritional support in critically ill obese patients are needed.

74 a patients but also in a small subset of non-obese patients, are associated with more severe asthma.

75 patients but not in "metabolically healthy" obese patients at early stage in insulin resistance.

76 feriority trial enrolling 8910 overweight or obese patients at increased cardiovascular risk from Jun

77 Among overweight or obese patients at increased cardiovascular risk, based o

78 were measured simultaneously in 26 severely obese patients before and 1 year after RYGB, while patie

79 died brain glucose metabolism in 22 morbidly obese patients before and 6 months after bariatric surge

80 tes with elements of fat balance in severely obese patients before and after RYGB.

81 Steatorrhea and hyperoxaluria were common in obese patients before bypass, but hyperoxaluria was not

82 Overweight or obese patients (BMI >25 kg/m(2)) had a higher rate of ca

83 ociated with a lower mortality risk, whereas obese patients (BMI >30 kg/m(2)) had a mortality risk si

84 The delay was longer in obese patients [BMI (in kg/m(2)) >/=30; n = 663] than in

85 bsolute differences were greater in severely obese patients (body mass index > 40 kg/m2), but were no

86 We prospectively followed 208 overweight or obese patients (body mass index [BMI] >/=25 kg/m(2)) rec

87 In obese patients (body mass index, 48 +/- 11 kg/m), 21.7 +

88 Participants consisted of 1236 obese patients (body mass index=48.4+/-7.6 kg/m), enroll

89 nd care needs of the critically ill morbidly obese patient but also navigate, both personally and pro

90 diovascular protection in normal weight than obese patients, but amlodipine-based therapy is equally

91 riodontal disease and OSAS risk in Class III obese patients, but OSAS risk was associated with both N

92 induces significant weight loss for severely obese patients, but there is limited evidence of the dur

93 Thus, in obese patients, clinical markers of a prothrombotic stat

94 more prominent in the proximal tubules of 15 obese patients compared with 16 non-obese patients.

95 e data demonstrating a different response in obese patients compared with normal-weight patients duri

96 The gingival tissue miRNA profile of obese patients, compared to that of normal weight patien

97 Obese patients demonstrate greater adverse LV remodeling

98 end-expiratory pressure, all critically ill obese patients demonstrated expiratory flow limitation (

99 Approximately 20-30% of obese patients do not achieve successful weight outcomes

100 , there is some evidence that full dosing in obese patients does not result in increased toxicity.

101 sing therapeutic target for the treatment of obese patients.Elevated plasma LPS levels have been asso

102 Morbidly obese patients exhibit impaired secretion of gut hormone

103 Obese patients exhibited higher expression levels of IL-

104 Five nonobese and two obese patients experienced potentially toxic piperacilli

105 Five severely obese patients (four women, one man) who were 31-49 year

106 and June 2014 that recruited overweight and obese patients from primary care; provided behavioral co

107 iences of caring for critically ill morbidly obese patients from the perspectives of intensive care s

108 The control group consisted of 80 diabetic obese patients from the same period with similar body ma

109 mplications with VH repair (VHR) increase in obese patients (grade A), current smokers (grade A), and

110 mplications with VH repair (VHR) increase in obese patients (grade A), current smokers (grade A), and

111 ainly expressed DAPK2 and that DAPK2 mRNA in obese patients gradually recovered after bariatric surge

112 0.001), and after adjusting for confounders, obese patients had a significantly higher rate of tooth

113 similar among categories, but overweight and obese patients had longer hospital lengths of stay than

114 no significant differences in infarct size, obese patients had significantly more impaired LV global

115 Morbidly obese patients had the highest proportion (87%) of no si

116 Most obese patients have high endogenous levels of leptin, in

117 Obese patients have impaired vasodilator reactivity and

118 In conclusion, obese patients have increased risk for DGF.

119 Prior studies have found that obese patients have paradoxically lower in-hospital mort

120 ity have the best survival, whereas morbidly obese patients have the highest mortality.

121 Obese patients have worse outcomes during acute pancreat

122 0.80-1.09; OR: 0.95, 95% CI: 0.81-1.12) and obese patients (HR: 1.07, 95% CI: 0.78-1.48; OR: 0.96, 9

123 Obese patients in all weight classes are at an increased

124 For most morbidly obese patients, in addition to causing significant weigh

125 alyses, hypertension rates were higher among obese patients (incidence rate ratio [IRR] 1.70, 95% con

126 e, adipocyte-conditioned media obtained from obese patients increased IL32 gene expression in human m

127 The benefit of renal transplantation in obese patients is controversial, with many centers setti

128 ve prevention and treatment of thrombosis in obese patients is limited by an incomplete understanding

129 positive end-expiratory pressure in morbidly obese patients is not well defined.

130 on, the survival of organs transplanted into obese patients is reduced compared with allografts in le

131 dipose tissue macrophages in type 2 diabetic obese patients, mainly driven by increased NLRP3-depende

132 In obese patients, MAIT cells were more abundant in adipose

133 Morbidly obese patients may be at increased risk of delayed graft

134 is not linear, where overweight and class I obese patients may have an improvement in outcome.

135 Three groups were studied: morbidly obese patients (n = 16), morbidly obese patients who had

136 Overweight (n = 737) and obese patients (n = 334) had higher prevalence of hypert

137 Compared to obese patients, nonobese patients had lower NAFLD activi

138 Bariatric surgery in obese patients not only improved their metabolic paramet

139 Twenty-seven obese patients (Ob) with T2D, 15 Ln-T2D, and 12 normal-w

140 atio = 0.59; 95% CI, 0.39-0.88) and severely obese patients (odds ratio = 0.46; 95% CI, 0.26-0.80) ha

141 Highest VTE risk was seen in obese patients [odds ratio (OR) = 1.41], those older tha

142 s was especially lower with statin use among obese patients (OR = 0.26; 95% CI: 0.09-0.71), as was th

143 rmal weight, 21.9 in overweight, and 18.2 in obese patients (overall p=0.0034).

144 erior to ARFI for diagnosing any fibrosis in obese patients (P < 0.001) but not in nonobese patients

145 y and Medicare expenditures were greater for obese patients (p < 0.01 for both comparisons), but aver

146 , the relationship trended to be inverse for obese patients (P = .11, rho = -0.36).

147 erweight patients, and 1.06 (1.00, 1.12) for obese patients (P = 0.004).

148 ients (P=0.020), and 41% higher for morbidly obese patients (P=0.015).

149 verweight patients (P=0.077), 28% higher for obese patients (P=0.020), and 41% higher for morbidly ob

150 (1.2 [0.6-4] vs 10 [5-12.5] cm H2O in supine obese patients; p < 0.001) and plateau pressure (15.6 [1

151 me, 0% [0-58%] vs 59.4% [51-81.4%] in supine obese patients; p < 0.001) but also results in a signifi

152 (15.6 [14-17] vs 22 [18-24] cm H2O in supine obese patients; p < 0.001).

153 Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had

154 Results In this obese patient population (mean body mass index = 40.3 kg

155 Conclusion In this obese patient population, both MR elastography and VCTE

156 Critically ill morbidly obese patients pose considerable healthcare delivery and

157 ed for specific protocols to manage morbidly obese patients presenting to the ED with chest pain and

158 e advanced stage at diagnosis, with 72.5% of obese patients presenting with metastatic disease versus

159 Severely obese patients, prior to bypass, ingest excess dietary f

160 Sixty-six morbidly obese patients randomized to SG or RYGB were included in

161 Obese patients rarely achieve long-term weight loss with

162 biopsies and serum samples from 113 morbidly obese patients receiving bariatric surgery, healthy indi

163 Among obese patients receiving care in the VA health system, t

164 alcoholic fatty liver disease (NAFLD) in non-obese patients remains a clinical condition with unclear

165 Optimal chemotherapy dosing in obese patients remains uncertain, with variation in prac

166 Morbidly obese patients selected for LRYGB were included in a pro

167 Consecutive morbidly obese patients selected for LSG were included in a prosp

168 in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutr

169 Morbidly obese patients should be considered potential candidates

170 Preliminary data in a small cohort of obese patients show a similar association.

171 3.7 years (interquartile range: 2.5 to 5.3), obese patients showed an HR of 3.6 (95% CI: 1.2 to 10.7,

172 preadipocyte cocultures exposed to sera from obese patients stimulated greater breast cancer cell ERa

173 Exposure to sera from obese patients stimulated greater macrophage COX-2 expre

174 In obese patients the risk of an ED visit or hospitalizatio

175 Among obese patients, the forced expiratory volume in 1 s (FEV

176 In obese patients, the total number of enteroendocrine cell

177 odontal treatment was better among lean than obese patients; the remaining three studies did not repo

178 toperative course after major hepatectomy in obese patients through a case-matched study.

179 opportunity to prevent colorectal cancer in obese patients through hormone replacement with the FDA-

180 k may be biased by preferential admission of obese patients to ICUs, and little is known about other

181 cians could consider referring overweight or obese patients to Weight Watchers or Jenny Craig.

182 There is no guidance on dose for obese patients treated with biologic agents.

183 for severe obesity, less than 1% of severely obese patients undergo it.

184 After matching, obese patients undergoing a surgical procedure demonstra

185 es; and SAT, VAT, and liver tissues from 113 obese patients undergoing bariatric surgery at academic

186 er samples were collected from 19 additional obese patients undergoing bariatric surgery to determine

187 Finally, in obese patients undergoing bariatric surgery, the severit

188 In morbidly obese patients undergoing bariatric surgery, we show tha

189 s of adipocyte tissue macrophages (ATMs), in obese patients undergoing bariatric surgery.

190 aradox, morbidity and mortality are lower in obese patients undergoing cardiac surgery, although the

191 However, flap necrosis is a complication in obese patients undergoing this procedure.

192 Obese patients undergoing VHR from 2008 through 2009 wer

193 To control for medical complexity, each obese patient was matched one-to-one with a nonobese pat

194 A survival advantage for overweight and obese patients was observed in this large cohort of crit

195 Antrum area during fasting in morbidly obese patients was statistically significant larger than

196 We carried out a cross-sectional study of obese patients, well characterized with respect to the s

197 om 16 mechanically ventilated critically ill obese patients were analyzed.

198 ns between intensive care staff and morbidly obese patients were challenging due to the social stigma

199 We also found that less obese patients were less likely to have higher and susta

200 Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant t

201 osing of 16 g/2 g/24 hr continuous infusion, obese patients were more likely than nonobese patients t

202 Compared with normal/underweight patients, obese patients were younger and more likely to have diab

203 Obese patients were younger and more likely to have hype

204 Atelectasis develops in critically ill obese patients when undergoing mechanical ventilation du

205 1 was increased upon weight loss in morbidly obese patients, while Sparc expression was reduced.

206 gery may be most effective for younger, less obese patients who are early in the course of their card

207 We conclude that PI3Kgamma inhibition in obese patients who are predisposed to beta-cell failure

208 : morbidly obese patients (n = 16), morbidly obese patients who had had sleeve gastrectomy (n = 8), a

209 duction in the rate of HF exacerbation among obese patients who underwent nonbariatric surgery (i.e.,

210 We reviewed management issues in the obese patient with cancer, focusing on how obesity influ

211 endations for the surgical management of the obese patient with cancer.

212 from VA databases in overweight patients and obese patients with a weight-related disorder who had un

213 PATIENTS/Critically ill obese patients with acute respiratory failure and anesth

214 ardiorespiratory fitness on the prognosis of obese patients with AF.

215 A cohort of obese patients with and without type 2 diabetes mellitus

216 ed a less collapsible airway than overweight/obese patients with apnea (critical closing pressure: -3

217 y muscle responsiveness than both overweight/obese patients with apnea (Deltagenioglossus EMG/Deltaep

218 increased in the submucosa in a subgroup of obese patients with asthma (OAs).

219 a self-controlled case series study of 2261 obese patients with asthma aged 18 to 54 years who under

220 bronchial challenge and exercise testing in obese patients with asthma and misdiagnosed asthma compa

221 Fifty-five obese patients with asthma were randomly assigned to eit

222 Clinical control is difficult to achieve in obese patients with asthma.

223 ough May 2013, one hundred and nine morbidly obese patients with biopsy-proven NASH underwent bariatr

224 examine the clinical benefit of NSAID use in obese patients with breast cancer are warranted.

225 ve the diagnosis, treatment, and outcomes of obese patients with breast cancer.

226 Further, obese patients with cirrhosis alone and in combination w

227 reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension.

228 S) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduce

229 rmal weight patients (P=0.073), and morbidly obese patients with computerized tomographic scanning st

230 In morbidly obese patients with diabetes who were offered DSE, a pro

231 For most severely obese patients with diabetes, bariatric surgery seems to

232 D management, particularly in overweight and obese patients with difficult glycemic control; and futu

233 These data suggest that morbidly obese patients with end-stage renal disease who undergo

234 However, obese patients with ESRD have limited access to kidney t

235 ered the weight loss procedure of choice for obese patients with gastroesophageal reflux disease (GER

236 fective option for the surgical treatment of obese patients with GERD.

237 ormed a self-controlled case series study of obese patients with HF who underwent bariatric surgery,

238 e effects of substantial weight reduction in obese patients with HF.

239 iring ED evaluation or hospitalization among obese patients with HF.

240 se with nonobese HFpEF and control subjects, obese patients with HFpEF displayed worse exercise capac

241 hronic inflammation, we investigated whether obese patients with hip OA exhibited differential pro-in

242 collected from normal-weight or over-weight/obese patients with hip OA.

243 oth glycemic control and DPN in non-severely obese patients with insulin-dependent T2DM.

244 More obese patients with irreversible end-stage organ failure

245 rgy diet (LED) reduces weight effectively in obese patients with knee osteoarthritis, but the role of

246 Obese patients with leptin resistance show a variable re

247 may be a safe and effective intervention for obese patients with LVSD.

248 We studied 24 obese patients with MC4R deficiency, and 80 healthy cont

249 HR) and 95% CIs were 1.45 (1.12 to 1.82) for obese patients with MetSyn (n = 480); 1.09 (0.83 to 1.44

250 iseases where overweight and at least mildly obese patients with most CV diseases seem to have a bett

251 14, at a private MS referral center among 50 obese patients with MS who also developed MetS.

252 therapeutic option for appropriate morbidly obese patients with NASH who do not respond to lifestyle

253 ry was both effective and cost-effective for obese patients with NASH, regardless of fibrosis stage;

254 erm effects of bariatric surgery in morbidly obese patients with NASH.

255 uman mINDY may have therapeutic potential in obese patients with nonalcoholic fatty liver disease.

256 am improves gut barrier function and whether obese patients with or without liver steatosis differ in

257 dysfunction, are significantly increased in obese patients with OSA versus those without OSA, sugges

258 ining the increase in tongue EMG activity in obese patients with OSA.

259 R was confirmed by qRT-PCR as being lower in obese patients with periodontitis versus normal weight p

260 ymptoms and controls reflux in most morbidly obese patients with preoperative GERD.

261 We further show that obese patients with prostate cancer have increased epith

262 a index, 4.7 +/- 3.1 events per hour) and 72 obese patients with sleep apnea (apnea-hypopnea index, 4

263 Intestinal permeability is increased in obese patients with steatosis compared with obese patien

264 Hence, obese patients with stroke should continue to aim for no

265 to uncertainty about secondary prevention in obese patients with stroke.

266 biopsy specimens obtained from 13 overweight/obese patients with T2D and 14 weight-matched male contr

267 peptide (GIP) in the splanchnic region in 10 obese patients with T2D before and after bariatric surge

268 Obese patients with T2D show a greater propensity for ec

269 ted an obesity paradox, where overweight and obese patients with these disorders have a better progno

270 We studied 10 obese patients with type 2 diabetes (T2D) and 10 obese g

271 nsported in LDL is elevated in the plasma of obese patients with type 2 diabetes and correlated with

272 dical treatment for the long-term control of obese patients with type 2 diabetes and should be consid

273 hanges of glucostatic parameters in morbidly obese patients with type 2 diabetes mellitus undergoing

274 Of the 173 obese patients with type 2 diabetes mellitus undergoing

275 A total of 27 obese patients with type 2 diabetes mellitus were random

276 nsitivity and beta-cell function in morbidly obese patients with type 2 diabetes mellitus who undergo

277 e long-term outcomes of 2 groups of morbidly obese patients with type 2 diabetes mellitus-1 managed b

278 tes, we randomly assigned 5145 overweight or obese patients with type 2 diabetes to participate in an

279 s for diabetes and weight loss strategies in obese patients with type 2 diabetes until larger randomi

280 In mild to moderately obese patients with type 2 diabetes, adding gastric bypa

281 y long-term follow-up observational study of obese patients with type 2 diabetes, bariatric surgery w

282 In obese patients with type 2 diabetes, RYGB produces great

283 glucose clamp (iso-IVGC) in: 1) 16 severely obese patients with type 2 diabetes, up to 3 years post-

284 Using experiments in mice and overweight/obese patients with type 2 diabetes, we elucidated the s

285 ovascular and macrovascular complications in obese patients with type 2 diabetes.

286 comes 3 years after the randomization of 150 obese patients with uncontrolled type 2 diabetes to rece

287 Among obese patients with uncontrolled type 2 diabetes, 3 year

288 ty-associated HCC, we measured plasma TnC in obese patients with various levels of liver injury.

289 tively screen for diabetes in overweight and obese patients with vascular disease, and pay increased

290 Our results showed that surgery and ILI in obese patients (with F0-F3) increased QALYs by 0.678-2.1

291 nd genus levels between healthy subjects and obese patients (with or without NASH), and relatively fe

292 Obese and seriously obese patients, with a body mass index of 30-39.9 kg/m,

293 Ongoing alcohol drinkers and morbidly obese patients, with minimal hepatic injury and steatosi

294 Morbidly obese patients without computerized tomographic scanning

295 Twelve obese patients without diabetes (8 women, mean age 43.1

296 etSyn (n = 417), and 1.00 (0.80 to 1.26) for obese patients without MetSyn (n = 324).

297 In obese patients without preoperative evidence of GERD, th

298 ded and matched by propensity score to 3,882 obese patients without surgery.

299 obese patients with steatosis compared with obese patients without.

300 atory pressure; p < 0.001) in almost all the obese patients, without increasing plateau pressure (24